X4 Pharmaceuticals, Inc.
XFOR
$4.10
$0.030.74%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 79.08% | 215.18% | 250.44% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 79.08% | 215.18% | 250.44% | -- | -- |
| Cost of Revenue | 20.53% | 54.63% | 21.64% | -- | -- |
| Gross Profit | 94.70% | 324.62% | 458.31% | -- | -- |
| SG&A Expenses | -51.26% | -47.73% | -28.25% | -13.85% | 52.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.75% | -30.48% | -18.15% | 2.58% | 47.42% |
| Operating Income | 33.08% | 34.47% | 22.61% | 74.68% | -41.73% |
| Income Before Tax | 39.53% | 18.64% | -128.29% | 100.61% | -107.17% |
| Income Tax Expenses | -100.00% | -300.00% | 105.56% | 78.95% | 681.82% |
| Earnings from Continuing Operations | 39.92% | 18.75% | -128.34% | 100.54% | -108.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.92% | 18.75% | -128.34% | 100.54% | -108.16% |
| EBIT | 33.08% | 34.47% | 22.61% | 74.68% | -41.73% |
| EBITDA | 33.20% | 34.61% | 23.22% | 75.91% | -41.00% |
| EPS Basic | 96.32% | 87.43% | -125.54% | 100.53% | -103.89% |
| Normalized Basic EPS | 96.27% | 89.48% | -63.73% | 100.60% | -102.91% |
| EPS Diluted | 96.32% | 87.41% | -125.59% | 100.51% | -103.07% |
| Normalized Diluted EPS | 96.27% | 89.48% | -64.03% | 100.59% | -102.91% |
| Average Basic Shares Outstanding | 1,534.38% | 546.30% | 10.95% | 2.60% | 2.10% |
| Average Diluted Shares Outstanding | 1,534.38% | 546.30% | 10.75% | 3.04% | 2.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |